David Dayen

David Dayen is a contributing writer to Salon.com who also writes for The InterceptThe New Republic, and The Fiscal Times. His first book, Chain of Title, about three ordinary Americans who uncover Wall Street's foreclosure fraud, was released by The New Press on May 17, 2016.

Recent Articles

Why the Aetna and CVS Merger Is So Dangerous

Aetna and CVS have more incentive than ever to use their market power to crush competition, and the Justice Department just gave them the opportunity.

(AP Photo/Mark Lennihan)
(AP Photo/Mark Lennihan) T his week, the Justice Department blessed a $69 billion merger between pharmacy chain CVS and insurance giant Aetna. CVS also owns Caremark, one of the three largest pharmacy benefit managers (PBMs), which negotiate drug discounts on behalf of health plans. With another tie-up between a PBM and an insurance company—Express Scripts and Cigna—awaiting likely approval, this signals an almost formal merger between the PBM industry and the health-insurance industry. When the CVS/Aetna merger was proposed, I wrote at the Prospect that this vertical combination would be incredibly dangerous. If CVS/Aetna knows the prescription drug usages, methods of delivery, and pricing data for all of its rivals, who all have patients who order prescriptions from CVS pharmacies, it can exploit that data advantage to skim off the top of every side of the pharmaceutical market. But a funny thing happened on the way to the deal closing. Congress, state legislatures, and even the...

How BlackRock Rules the World

The planet’s largest investment fund handles Mexico’s pension funds—and owns the companies they invest in. Cozy!

(Laurent Gillieron/Keystone via AP)
(Laurent Gillieron/Keystone via AP) BlackRock CEO Larry Fink speaks during a panel session at the World Economic Forum meeting in Davos, Switzerland, on January 25, 2018. A new pecking order has emerged on Wall Street. Big banks remain powerful and incredibly profitable—quarterly income has hit record levels throughout 2018, largely due to benefits from the tax cuts. But a decade of financial crisis, regulatory pressures, and (most important) new investing trends has transferred power to a few dominant asset management firms. As more Americans plow retirement savings into passive funds, the buy side has overtaken the sell side . Buoyed by an index fund collection called iShares that it purchased from Barclays, BlackRock is the world’s largest asset manager, with $6.3 trillion of other people’s money under its control. BlackRock’s Aladdin risk-management system , a software tool that can track and analyze trading, monitors a whopping $18 trillion in assets for 200 financial firms; even...

Schumer Surrenders

The Democrats’ Senate leader lets Mitch McConnell pack the courts.

(AP Photo/J. Scott Applewhite)
(AP Photo/J. Scott Applewhite) Senate Minority Leader Chuck Schumer on August 21, 2018 D emocrats were obviously focused on the departure of Barack Obama from the political scene in 2017. But the exit of another Democratic leader, Senator Harry Reid, while not quite as consequential as losing the presidency, has proven damaging. A Senate leader is potentially the most powerful figure of an opposition party, something Mitch McConnell showed adeptly throughout the Obama presidency, as he constantly frustrated Democratic aims. But under Chuck Schumer, those oppositional tactics have withered, producing jaw-dropping spectacles like the one we saw this week: the active collaboration of Democrats in fast-tracking lifetime appointments to the federal bench. Since passage of the 2017 tax law, the Senate has become little more than a confirmation factory for President Donald Trump’s appointees, and McConnell has badly outplayed Schumer in getting the job done. Sixty of Trump’s judicial...

Trump Eliminates the Middleman

His administration takes aim at the heretofore legal kickbacks to prescription drug distributors—but leaves the drug companies themselves untouched.

AP Photo/Jeff Roberson, File A building on the Express Scripts campus in Berkeley, Missouri A fter a massive corporate tax cut and widespread deregulation, there aren’t many industries fearing that the Trump administration will put them out of business—with one exception. An industry responsible for extracting billions of dollars in profits from prescription drug purchases could soon see its gravy train disappear. I’m not talking about drug manufacturers; they continue to skate by with fake concessions and half-measures. In fact, the Trump administration’s most aggressive actions on drug prices have been undertaken on behalf of Big Pharma. Sadly, that’s often how things get done in Washington, where corporate greed only gets struck down when pitted against a more powerful corporate adversary. It would be far preferable to overhaul the entire system causing drug prices to spiral out of control, but I guess you must start somewhere. The Department of Health and Human Services (HHS) and...

Bank Deregulation 2.0 Is Here

A new bill supported by both Democrats and Republicans is yet another deregulatory action that gives Wall Street room to run in dangerous directions.

(AP Photo/Jacquelyn Martin)
(AP Photo/Jacquelyn Martin) House Committee on Financial Services Ranking Member Maxine Waters and Committee Chair Jeb Hensarling listen during a hearing on July 18, 2018. J ust a couple months after Congress weakened financial rules and chipped away at the Dodd-Frank Act, bank deregulation 2.0 is here. It’s following the common script for financial system corruption, with a toxic mix of legislative hatchet jobs and official neglect that enables Wall Street players to recklessly pile on more risk. The bipartisan nature of the effort is also sadly par for the course, but that doesn’t excuse Democrats from their historical amnesia about the last time the banks got their way. Bank deregulation 1.0 was known as the Crapo bill, as much a commentary on its content as its main author, Senate Banking Committee Chair Mike Crapo. It significantly degraded Dodd-Frank, stripping enhanced regulations from banks with up to $250 billion in assets and reversing data disclosures that could have...

Pages